In in vitro studies, metformin, an oral antidiabetic medication, demonstrated the ability to reduce NLK expression and inhibit cell proliferation in NSCLC cell cultures, indicating its potential as a therapeutic option for NSCLC [66]. This evidence concerns the gene NLK and non-small cell lung carcinoma.